Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Multicentre Phase II Trial of Paclitaxel and Carboplatin with Concurrent Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

ROGER TELL, CHRISTER SEDERHOLM, CLAES KLINTENBERG, LARS FRANKSSON, EVA BRANDÉN, GUNNAR HILLERDAL, ULF LÖNN, CARL-JOHAN LINDÉN, SVEN-BÖRJE EWERS, KRISTINA LAMBERG, EVA MRAZEK, BRITTA LÖDÉN, ANDERS SJÖGREN, THOMAS LINNÉ, SIGNE FRIESLAND and FLORIN SIRZÉN
Anticancer Research September 2008, 28 (5B) 2851-2857;
ROGER TELL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tell_roger@lilly.com roger.tell@ki.se
CHRISTER SEDERHOLM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CLAES KLINTENBERG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LARS FRANKSSON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EVA BRANDÉN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GUNNAR HILLERDAL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ULF LÖNN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CARL-JOHAN LINDÉN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SVEN-BÖRJE EWERS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KRISTINA LAMBERG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EVA MRAZEK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BRITTA LÖDÉN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANDERS SJÖGREN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
THOMAS LINNÉ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SIGNE FRIESLAND
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FLORIN SIRZÉN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: To evaluate weekly induction chemotherapy followed by weekly concomitant chemoradiotherapy in a multicentre phase II study of patients with unresectable stage III non-small cell lung cancer (NSCLC; stage wet IIIB excluded). Patients and Methods: Eligible patients received three weekly cycles of paclitaxel 100 mg/m2 and carboplatin AUC2 followed by six weekly cycles of paclitaxel 60 mg/m2 and carboplatin AUC2 in combination with thoracic radiotherapy (2 Gy per fraction and day to a total dose of 60 Gy). Results: Sixty-four patients (40 males and 24 females) with a median age of 63 years (range, 43-79 years) entered the study. T and N stage were distributed as follows: T1 2 patients (3.2%), T2 10 patients (15.6%), T3 15 patients (23.4%), T4 37 patients (57.8%); N0 10 patients (15.6%), N1 1 patient (1.6%), N2 26 patients (40.6%), N3 26 patients (40.6%), and N missing 1 patient (1.6%). Seven patients (10.9%) suffered from grade 3/4 oesophagitis. Grade 1/2 oesophagitis occurred in 36 patients (56.3%) and pneumonitis grade 1/2 occurred in 10 patients (15.6%). Sixty-three patients were evaluated on an intent-to-treat basis. The overall response rate was 74.6% . The median time to progression was 247 days and median overall survival was 461 days. According to subgroup analyses, no statistically significant differences were noted according to gender, age (<65 vs. ≥65 years), performance status, histology, or study centre. Conclusion: Induction chemotherapy followed by concurrent chemoradiotherapy with weekly cycles of paclitaxel and carboplatin is feasible and generates moderate toxicity. Efficacy is comparable to other recently published regimens. However, prognosis remains, in general, poor for this group of patients and further work to develop better therapy is required.

  • Non-small cell lung cancer
  • phase II study
  • induction chemotherapy
  • paclitaxel
  • carboplatin
  • chemoradiotherapy

Footnotes

  • ↵* At the time of study initiation.

  • Received March 18, 2008.
  • Revision received June 30, 2008.
  • Accepted July 7, 2008.
  • Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 28 (5B)
Anticancer Research
Vol. 28, Issue 5B
September-October 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Multicentre Phase II Trial of Paclitaxel and Carboplatin with Concurrent Radiotherapy in Locally Advanced Non-small Cell Lung Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Multicentre Phase II Trial of Paclitaxel and Carboplatin with Concurrent Radiotherapy in Locally Advanced Non-small Cell Lung Cancer
ROGER TELL, CHRISTER SEDERHOLM, CLAES KLINTENBERG, LARS FRANKSSON, EVA BRANDÉN, GUNNAR HILLERDAL, ULF LÖNN, CARL-JOHAN LINDÉN, SVEN-BÖRJE EWERS, KRISTINA LAMBERG, EVA MRAZEK, BRITTA LÖDÉN, ANDERS SJÖGREN, THOMAS LINNÉ, SIGNE FRIESLAND, FLORIN SIRZÉN
Anticancer Research Sep 2008, 28 (5B) 2851-2857;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Multicentre Phase II Trial of Paclitaxel and Carboplatin with Concurrent Radiotherapy in Locally Advanced Non-small Cell Lung Cancer
ROGER TELL, CHRISTER SEDERHOLM, CLAES KLINTENBERG, LARS FRANKSSON, EVA BRANDÉN, GUNNAR HILLERDAL, ULF LÖNN, CARL-JOHAN LINDÉN, SVEN-BÖRJE EWERS, KRISTINA LAMBERG, EVA MRAZEK, BRITTA LÖDÉN, ANDERS SJÖGREN, THOMAS LINNÉ, SIGNE FRIESLAND, FLORIN SIRZÉN
Anticancer Research Sep 2008, 28 (5B) 2851-2857;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Gastrojejunostomy for Asymptomatic Gastric Outlet Obstruction in Pancreatic Cancer May Contribute to Early Recovery
  • Feasibility of an Exercise Training Program Among Patients With Newly Diagnosed Advanced Breast Cancer
  • Impact of Surgery Refusal on Overall Survival in Merkel Cell Carcinoma
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire